Oncology Central

Promising new strategies to target gene regulatory factors in T-cell acute lymphoblastic leukemia


There has been tremendous progress in the treatment of acute lymphoblastic leukemia (ALL) with modern chemotherapeutic regimens, especially in pediatric cases. However, patients with T-cell acute lymphoblastic leukemia (T-ALL) have a higher risk for early relapse than those with other ALL subtypes, and these cases have a substantially poorer overall prognosis [1].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.